Trial Profile

A Phase 1, Two-part, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPR206 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SPR-206 (Primary)
Indications Acinetobacter infections; Gram-negative infections; Intra-abdominal infections; Urinary tract infections
Focus Adverse reactions; First in man
Sponsors Spero Therapeutics

Most Recent Events

02 Aug 2021 Results (n=94) assessing safety, tolerability, and pharmacokinetics of SPR206 in healthy subjects, published in the Antimicrobial Agents and Chemotherapy.
16 Mar 2020 According to an Spero Therapeutics media release, Spero expects to present final data from the Phase 1 clinical trial in the first half of 2020
08 Jan 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com